Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy

G. Di Minno, G. Castaman, Raimondo De Cristofaro, N. Brunetti-Pierri, L. Pastore, G. Castaldo, Ugo Trama, M. Di Minno

Research output: Contribution to journalArticle

Abstract

In persons with congenital severe hemophilia A (HA) living in high-income countries, twice weekly intravenous infusions of extended half-life (EHL) factor VIII (FVIII) products, or weekly/biweekly/monthly subcutaneous injections of emicizumab are the gold standard home treatments to grant days without hurdles and limitations. Once weekly/twice monthly infusions of EHL Factor IX (FIX) products achieve the same target in severe hemophilia B (HB). Gene therapy, which is likely to be licensed for clinical use within 1–2 years, embodies a shift beyond these standards. At an individual patient level, a single functional gene transfer leads to a > 10-yr almost full correction of the hemostatic defect in HB and to a sustained (3–6-yrs) expression of FVIII sufficient to discontinue exogenous clotting factor administrations. At the doses employed, the limited liver toxicity of systemically infused recombinant adeno-associated virus (rAAV) vectors is documented by long-term (12–15 yrs) follow-ups, and pre-existing high-titer neutralizing antibodies to the AAV5 vector are no longer an exclusion criterion for effective transgene expression with this vector. A safe durable treatment that converts a challenging illness to a phenotypically curable disease, allows persons to feel virtually free from the fears and the obligations of hemophilia for years/decades. Along with patient organizations and health care professionals, communicating to government authorities and reimbursement agencies the liberating potential of this substantial innovation, and disseminating across the Centers updated information on benefits and risks of this strategy, will align expectations of different stakeholders and establish the notion of a potentially lifelong cure of hemophilia.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalBlood Reviews
Volume58
DOIs
Publication statusPublished - 2023

Keywords

  • Benefits, theoretical risks
  • Coagulation factor inhibitors
  • Educational programs
  • Extended half-life products
  • Government bodies
  • Reimbursement agencies
  • Laboratory monitoring
  • Non-substitutive therapies
  • Patient organizations
  • Prospective registries
  • Quality of life
  • Health care professionals

Fingerprint

Dive into the research topics of 'Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy'. Together they form a unique fingerprint.

Cite this